Abstract Dystrophin, the protein product of the Duchenne muscular dystrophy (DMD) gene, was studied in 19 patients with Xp2l disorders and in 25 individuals with nonXp21 muscular dystrophy. Antibodies raised to seven different regions spanning most of the protein were used for immunocytochemistry. In all patients specific dystrophin staining anomalies were detected and correlated with clinical severity and also gene deletion. In patients with Becker muscular dystrophy (BMD) the anomalies detected ranged from interand intra-fibre variation in labelling intensity with the same antibody or several antibodies to general reduction in staining and discontinuous staining. In vitro evidence of abnormal dystrophin breakdown was observed reanalysing the muscle ofpatients, with BMD and not that of non-Xp2l dystrophies, after it had been stored for several months. A number of patients with DMD showed some staining but this did not represent a diagnostic problem. Based on the data presented, it was concluded that immunocytochemistry is a powerful technique in the prognostic diagnosis of Xp2l muscular dystrophies.
Abstract Dystrophin, the protein product of the Duchenne muscular dystrophy (DMD) gene, was studied in 19 patients with Xp2l disorders and in 25 individuals with nonXp21 muscular dystrophy. Antibodies raised to seven different regions spanning most of the protein were used for immunocytochemistry. In all patients specific dystrophin staining anomalies were detected and correlated with clinical severity and also gene deletion. In patients with Becker muscular dystrophy (BMD) the anomalies detected ranged from interand intra-fibre variation in labelling intensity with the same antibody or several antibodies to general reduction in staining and discontinuous staining. In vitro evidence of abnormal dystrophin breakdown was observed reanalysing the muscle ofpatients, with BMD and not that of non-Xp2l dystrophies, after it had been stored for several months. A number of patients with DMD showed some staining but this did not represent a diagnostic problem. Based on the data presented, it was concluded that immunocytochemistry is a powerful technique in the prognostic diagnosis of Xp2l muscular dystrophies. ( fig 3) . A discordance in staining between the various antibodies was the second most frequent abnormality. This was also noted in patients with very mild or preclinical phenotypes, in which the use of just one or two antidystrophin antibodies gave normal results when taken individually. Only the comparison of results obtained with antibodies raised against different portions of the protein was revealing in these mildly affected individuals. Several patients had deletions of the cDNA in a region partially encompassed by one of the antibodies used (for example BMD 2 for H12 antibody) which gave a very faint signal in this subset of cases. A discontinuous labelling of the membrane was the third most common abnormality, but was confined to patients in the moderate/severe range of BMD ( fig 4) ; rare dystrophin negative fibres were detected in these subjects (table 1) . No specific immunofluorescence abnormality was detected in the 25 patients with non-Xp2 1 dystrophies except 
Pattern of dystrophin abnormalities in DMD patients
The greater number ofboys with DMD had no detectable dystrophin with most of the antibodies used (table 2) . In a few patients (3/10) a very faint immunoreactivity, correctly located at the periphery of the muscle fibres, was detected in the majority of fibres using D1-2 and 90K N-terminal antibodies, but not with all remaining antibodies. The same phenomenon was observed in the muscle of a DMD foetus. A progressive loss of this weak immunoreactivity was also observed in this subgroup of patients with DMD when retested after 3 weeks and up to a couple of months. When muscle of boys with DMD was analysed using the complete panel of antidystrophin antibodies, the following exceptions to the rule "dystrophin absence = DMD" were detected: a) Scattered positive fibres in DMD. Occurrence of scattered muscle fibres showing normal immunoreactive sarcolemmal dystrophin was noted in most of the boys with DMD (table 2  and fig 5) . The occurrence of these positive fibres was detected with all antibodies used. Immunoreactivity could often be followed, using several serial sections, for more than 1 20p (that is, more than 20 slices) in the majority of cases; sometimes positivity was followed for more than 200,u before the positive signal was lost. The same phenomenon was found in a DMD foetus (14 weeks), in which the presence of rare positive myotubes (as opposed to negative myotubes) was detected. b)Dystrophin immunoreactivity in the muscle spindle of a boy with DMD. The intrafusal fibres of a muscle spindle of a boy with DMD (patient 41) were very brightly stained with all The symbol + or -under the heading READING-FRAME indicates the maintenance of reading frame.
The symbol ( §) indicates tha some labelling was detectable only with N-terminal antibodies.
antibodies used. In figure 6 immunoreactivity obtained with 90K antibody is shown: perinuclear staining was detected only with this antibody. The strong positive immunoreactivity was followed, in serial sections, for approximately 140,u (20 slices), but disappeared thereafter in all fibres. c)Split fibres. In DMD, the newly synthesised membrane of a splitting fibre frequently displayed low levels of dystrophin immunoreactivity although the periphery of muscle fibres was negative (fig 7) . This positivity was detected with all antibodies. Splits (and vacuoles) were always strongly positive in BMD and non-Xp2l disorders. Very weak immunostaining was detected in the three patients with an intermediate phenotype. Patient 86 (deleted for exons 3-9) and 63 (exons 3-7 deleted) showed no immunoreactivity with the most N-terminal antibody D 1-2, raised against an epitope partially deleted in these two patients (fig 8a) , but starting from antibody 90K and as far as the most C-terminal antibody a clear, although very weak immunoreactivity was detected ( fig  8b) ; several dystrophin-negative fibres were also present ( Discussion Dystrophin deficiency has been well documented as the underlying cause of Duchenne muscular dystrophy by both immunofluorescence and immunoblot analysis.39 '4 Abnormalities in the quantity and/or quality of dystrophin have also been well characterised in patients with BMD.3 68 In the main part of the original studies only one (N-terminal) antibody was used. In this study we have selected a panel of 7 different anti dystrophin antibodies and immunofluorescence analysis in a group of 19 patients with Xp21 disorders.
In patients with BMD we were able to identify different kinds of abnormalities related to phenotype severity. We established that the most frequent abnormalities in our BMD patients were staining variability between individual fibres (using one antibody) and differences in staining intensity when several antibodies were employed. The use of a complete set of antibodies enabled us to identify very subtle anomalies that cannot be detected with the use of only one antibody in the BMD patients (our data and 8).
A further useful test to reveal abnormalities in patients with very mild BMD was that of restaining serial sections of muscle after storing it for several months: almost invariably a reduction in staining intensity was detected in muscle of BMD patients. We believe that staining reduction is probably a marker of increased in vitro dystrophin instability because: no reduction in staining was detectable in control muscle (and 
